Hypothesis

Inserting a short, pH‑responsive fusogenic peptide into the exosome membrane via a tetraspanin‑anchored lipid scaffold creates controllable nanopores that markedly increase the encapsulation efficiency of CRISPR‑Cas9 ribonucleoprotein (RNP) complexes while preserving vesicle integrity and low immunogenicity.

Mechanistic Rationale

Exosomes naturally exploit tetraspanin‑enriched microdomains to organize cargo‑sorting machinery such as hnRNPA2B1, which recognizes EXOmotif sequences in RNAs and coordinates with CD9/CD63/CD81/CD82 for vesicle biogenesis[hnRNPA2B1 EXOmotif binding]. By genetically fusing a membrane‑anchoring domain of CD63 to a synthetic lipid‑PEG conjugate bearing a fusogenic peptide (e.g., GALA), we propose to generate localized lipid disorder that transiently opens nanoscale pores upon endosomal acidification. This design leverages two orthogonal advantages: (1) the intrinsic CD47 “don’t eat me” signal confers immune evasion[Exosome biocompatibility and CD47], and (2) the tetraspanin scaffold ensures spatial precision, preventing indiscriminate membrane disruption that could trigger complement activation or rapid clearance.

Current active loading methods (electroporation, extrusion) achieve modest RNP encapsulation (<15%) and risk cargo degradation[Exosome PTX loading extrusion]. Exosome‑liposome hybrids improve CRISPR‑Cas9 delivery but retain heterogeneity from liposome populations[Exosome‑liposome hybrids CRISPR]. Our approach maintains a purely exosomal bilayer, preserving the native RNA‑binding protein repertoire that could further guide RNP sorting via electrostatic interactions with exposed phosphates on the Cas9 protein.

Testable Predictions

1. Exosomes displaying the CD63‑PEG‑GALA construct will show ≥2‑fold higher Cas9 protein loading measured by western blot compared to unmodified exosomes after identical incubation conditions.
2. Encapsulated Cas9 will retain >80% nuclease activity in vitro, as assessed by a plasmid cleavage assay, indicating minimal peptide‑induced denaturation.
3. In cultured HEK293 cells expressing a GFP reporter, delivery of Cas9‑sgRNA via engineered exosomes will produce ≥30% GFP‑negative cells, a significant increase over free RNP or standard exosome loading.
4. In vivo biodistribution studies in mice will reveal reduced hepatic accumulation and prolonged circulation half‑life relative to PEGylated liposomes, reflecting preserved CD47-mediated immune evasion.

Experimental Approach

• Construct design: Clone CD63 cytosolic tail fused to a C‑terminal Gly‑Ser linker, then attach a DSPE‑PEG2000‑maleimide lipid via thiol‑chemistry; conjugate GALA peptide to the distal PEG terminus.
• Exosome production: Transfect HEK293 cells with the construct, isolate exosomes by differential ultracentrifugation followed by size‑exclusion chromatography to ensure purity.
• Loading assay: Incubate exosomes with Cas9‑sgRNA RNP at 37 °C for 1 h, separate free protein via ultrafiltration, quantify encapsulated Cas9 by BCA assay and western blot.
• Functional validation: Test nuclease activity on a fluorescent substrate, then treat GFP‑reporter cells and measure editing efficiency by flow cytometry.
• In vivo testing: Inject labeled exosomes intravenously in BALB/c mice, collect blood at multiple time points, and quantify exosomes by nanoparticle tracking analysis; assess organ fluorescence via IVIS imaging.

If the engineered nanopores do not improve RNP loading or compromise vesicle stability, the hypothesis will be falsified. Conversely, a demonstrable increase in functional delivery without heightened immune clearance would support a new paradigm for exosome‑based precision genome editing.